Nanovibronix Inc
NanoVibronix, Inc. is a medical device company focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The Company's primary products include PainShield and UroShield, which are portable devices suitable for administration at home or in any care setting. PainShield is a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy and decrease pain and discomfort associated with urinary catheter use.
Stock Performance Snapshot
Financial Health
Nanovibronix Inc is generating solid revenue and cash flow, indicating a healthy financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring NAOV
Injectable Drug Innovation Opportunities 2025
The FDA's approval of an at-home injectable version of Eisai and Biogen's Alzheimer's drug, Leqembi, simplifies treatment for patients and caregivers. This development highlights a growing trend toward patient-centric care, creating investment opportunities in companies that specialize in innovative drug delivery systems and at-home therapeutic technologies.
Published: August 31, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Small‑cap opportunity
As a micro‑cap, Nanovibronix can see large price moves if clinical or commercial news is positive; performance can also swing sharply the other way.
Clinical focus matters
Progress in clinical trials and regulatory clearances is fundamental to commercial adoption; investors should monitor published results and approvals.
Funding and risks
Limited cash or the need to raise capital can dilute shareholders, and limited trading volume can increase volatility — consider these risks carefully.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
